Stock Analysis on Net

Abbott Laboratories (NYSE:ABT) 

Adjustments to Financial Statements

Microsoft Excel

Adjustments to Current Assets

Abbott Laboratories, adjusted current assets

US$ in millions

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
As Reported
Current assets 23,656 22,670 25,224 24,239 20,441
Adjustments
Add: Allowance for doubtful accounts 247 241 262 313 288
After Adjustment
Adjusted current assets 23,903 22,911 25,486 24,552 20,729

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


Adjustments to Total Assets

Abbott Laboratories, adjusted total assets

US$ in millions

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
As Reported
Total assets 81,414 73,214 74,438 75,196 72,548
Adjustments
Add: Operating lease right-of-use asset (before adoption of FASB Topic 842)1
Add: Allowance for doubtful accounts 247 241 262 313 288
Less: Deferred tax assets2 8,623 982 1,044 1,206 1,163
After Adjustment
Adjusted total assets 73,038 72,473 73,656 74,303 71,673

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Operating lease right-of-use asset (before adoption of FASB Topic 842). See details »

2 Deferred tax assets. See details »


Adjustments to Total Liabilities

Abbott Laboratories, adjusted total liabilities

US$ in millions

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
As Reported
Total liabilities 33,513 34,387 37,533 39,172 39,545
Adjustments
Add: Operating lease liability (before adoption of FASB Topic 842)1
Less: Deferred tax liabilities2 512 568 991 1,392 1,406
Less: Restructuring Plans, accrued balance 9 58 256 84 70
After Adjustment
Adjusted total liabilities 32,992 33,761 36,286 37,696 38,069

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Operating lease liability (before adoption of FASB Topic 842). See details »

2 Deferred tax liabilities. See details »


Adjustments to Stockholders’ Equity

Abbott Laboratories, adjusted total Abbott shareholders’ investment

US$ in millions

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
As Reported
Total Abbott shareholders’ investment 47,664 38,603 36,686 35,802 32,784
Adjustments
Less: Net deferred tax assets (liabilities)1 8,111 414 53 (186) (243)
Add: Allowance for doubtful accounts 247 241 262 313 288
Add: Restructuring Plans, accrued balance 9 58 256 84 70
Add: Noncontrolling interests in subsidiaries 237 224 219 222 219
After Adjustment
Adjusted total shareholders’ investment 40,046 38,712 37,370 36,607 33,604

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Net deferred tax assets (liabilities). See details »


Adjustments to Capitalization Table

Abbott Laboratories, adjusted capitalization table

US$ in millions

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
As Reported
Short-term borrowings 213
Current portion of long-term debt 1,500 1,080 2,251 754 7
Long-term debt, excluding current portion 12,625 13,599 14,522 17,296 18,527
Total reported debt 14,125 14,679 16,773 18,050 18,747
Total Abbott shareholders’ investment 47,664 38,603 36,686 35,802 32,784
Total reported capital 61,789 53,282 53,459 53,852 51,531
Adjustments to Debt
Add: Operating lease liability (before adoption of FASB Topic 842)1
Add: Operating lease liability, current (included in Other accrued liabilities)2 254 245 230 245 241
Add: Operating lease liability, non-current3 896 949 943 956 902
Adjusted total debt 15,275 15,873 17,946 19,251 19,890
Adjustments to Equity
Less: Net deferred tax assets (liabilities)4 8,111 414 53 (186) (243)
Add: Allowance for doubtful accounts 247 241 262 313 288
Add: Restructuring Plans, accrued balance 9 58 256 84 70
Add: Noncontrolling interests in subsidiaries 237 224 219 222 219
Adjusted total shareholders’ investment 40,046 38,712 37,370 36,607 33,604
After Adjustment
Adjusted total capital 55,321 54,585 55,316 55,858 53,494

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Operating lease liability (before adoption of FASB Topic 842). See details »

2 Operating lease liability, current (included in Other accrued liabilities). See details »

3 Operating lease liability, non-current. See details »

4 Net deferred tax assets (liabilities). See details »


Adjustments to Reported Income

Abbott Laboratories, adjusted net earnings

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
As Reported
Net earnings 13,402 5,723 6,933 7,071 4,495
Adjustments
Add: Deferred income tax expense (benefit)1 (7,961) (461) (659) (509) (108)
Add: Increase (decrease) in allowance for doubtful accounts 6 (21) (51) 25 60
Add: Increase (decrease) in restructuring Plans, accrued balance (49) (183) 172 14 (9)
Less: Net earnings from discontinued operations, net of taxes 24
Add: Other comprehensive income (loss) (67) 212 323 572 (481)
After Adjustment
Adjusted net earnings 5,331 5,270 6,718 7,173 3,933

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Deferred income tax expense (benefit). See details »